Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) — FY26 Annual Report | 27 August 2026(3 announcements)

Jagsonpal Pharmaceuticals announced on August 27, 2026 that shareholders without registered email addresses received a letter providing a web-link and path to access the Annual Report 2025-26 and the notice of the 47th AGM scheduled for September 18, 2026 at 3:30 PM IST via video conference, with details on e-voting and participation procedures.

Jagsonpal Pharmaceuticals reported 7% revenue growth to ₹287 crore and 19% PAT growth to ₹43 crore in FY26, with a ₹1,907 million cash position and ₹400 million share buyback. It proposed a 200% dividend (including 75% special dividend) of ₹4 per share, completed an 85% stake acquisition in Aequitas Healthcare for ₹20.8 crore, and targeted ₹500 crore revenue by FY28. Key risks include regulatory pressures and operational transitions, while governance improvements and strong cash flow support shareholder returns and sustainable growth.

Jagsonpal Pharmaceuticals held its 47th AGM on September 18, 2026, approving FY26 results with revenue of ₹2,872.25 million and profit after tax of ₹430.82 million. The company proposed a 200% dividend (including [amount context mismatch] special dividend) payable by September 4, 2026, and approved a ₹400 million share buyback of 1.6 million shares at ₹250 each. Key strategic moves include the ₹20.8 crore acquisition of an 85% stake in Aequitas Healthcare to strengthen critical care presence, and a ₹40 crore equity buyback that improved ROCE to 25%. Shareholding shows promoters own 67.89% of equity. The filing highlights robust cash generation (₹614 crore free cash flow), 7% revenue growth, and 19% PAT growth, with targets of [amount context mismatch] crore revenue by FY28. Governance disclosures confirm compliance with SEBI norms, no material risks, and no related party transactions. Employee policies include 100% health insurance coverage and 5.12% salary increments.